<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in;font-family: 'Times New Roman',Times,serif">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 OR 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): April 24, 2009</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>TOMOTHERAPY INCORPORATED</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD nowrap align="center" valign="top"><B>Wisconsin
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>001-33452
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>39-1914727</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Commission File Number)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="48%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD align="center" valign="top"><B>1240 Deming Way<BR>
Madison, Wisconsin
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>&nbsp;<BR>53717</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(Address of principal executive offices)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(608) 824-2800</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B></B></DIV>

<DIV align="center" style="font-size: 10pt"><FONT style="border-top: 1px solid #000000">(Former name or former address, if changed since last report.)</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio --> </DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&nbsp;24, 2009, TomoTherapy Incorporated (the &#147;Company&#148;) entered into a Magnetron
Subscription Agreement (the &#147;Agreement&#148;) with an effective date of May&nbsp;1, 2009, with e2v Inc.,
having a business address at 520 White Plains Road, Suite&nbsp;450, Tarrytown, New York, 10591, and e2v
Technologies (UK)&nbsp;Limited having its principal place of business at 106 Waterhouse Lane,
Chelmsford, CM1 2QU, United Kingdom (collectively, &#147;E2V&#148;), for the manufacture, purchase, and sale
of magnetrons (the &#147;Magnetrons&#148;). The Agreement is in addition to the Long-Term Purchase Agreement
dated December&nbsp;22, 2008, between the Company and E2V for the purchase and sale of solid state
modulators, modulator accessories and magnetron accessories. The parties were previously doing
business for the purchase and sale of the Magnetrons strictly through purchase orders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">A magnetron is a key component in radiation therapy systems, used to supply radio frequency
energy to the linear accelerator.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the Agreement, the Company committed to purchasing all of its manufacturing
requirements for Magnetrons from E2V for the duration of the Agreement, commencing with an initial
36-month term. The Company has no minimum purchase obligation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the Agreement, the parties designed a Magnetron Subscription Program (&#147;MSP&#148;),
whereby the Company will pay E2V an agreed subscription price per TomoTherapy Hi Art system (the
&#147;System&#148;) listed in the subscription pool, payable monthly, to cover purchase, repair and
replacement for Magnetrons used in such Systems. Rather than providing a warranty, E2V provides a
repair and replacement program for the Magnetron on each System in the subscription pool. A credit
will be applied towards the first year&#146;s MSP price for Magnetrons already in use by the Company,
based on the average remaining life of the Magnetrons.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">E2V may adjust the subscription price accordingly if there is a 10% or greater change in the
number of beam on hours per System, taking into account evidence from the Company regarding whether
the change in beam on hours has affected the Magnetron consumption rate. The subscription price
may also be adjusted down following successful improvement initiatives by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Payment is due 45&nbsp;days from the invoice date and E2V allows a total credit line of $2.5
million for all products and services supplied to the Company, to be evaluated by the parties as
necessary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The parties agreed to convert the agreed upon subscription price from British pounds to U.S.
dollars on the next business day after May&nbsp;1, 2009 and each year of the Agreement thereafter, based
on a 12&nbsp;month forward rate exchange rate lock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company may purchase some Magnetrons outside of the MSP in order to build up or adjust
service inventory or for new product development work. Magnetrons purchased outside the MSP will
be covered under E2V&#146;s standard warranty against defects in materials and workmanship and failure
to meet the Company&#146;s specifications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company may reject Magnetrons that do not conform to the Company&#146;s specifications by
giving written notice to E2V within 45&nbsp;days from delivery. E2V may charge the Company a monthly
fee calculated based upon an estimated number of returned Magnetrons that the parties estimate that
E2V will determine do meet the agreed specifications even though the Company has rejected them (&#147;No
Fault Found Fee&#148;). Such No Fault Found Fee is subject to periodic adjustment if the actual number
of returned Magnetrons differs substantially from the estimated number. In the Agreement, the
parties affirmed their intention to collaborate to better align the Magnetron specifications with
the Company&#146;s performance expectations and testing procedures to attempt to reduce or eliminate the
No Fault Found Fee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In the event that any Magnetron is replaced by E2V with a new product or major revision, E2V
has agreed to give the Company 180&nbsp;days&#146; written notice before implementation. The Company may
reject
such new or revised product and may require E2V to supply the Company with unchanged
Magnetrons in accordance with the blanket purchase order quantities.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In the Agreement, the parties affirmed their intention to collaborate to improve the life
performance of the Magnetrons. To that end, E2V agreed to include enhancement programs within the
MSP, it being understood that certain other investigative work would incur non-recurring
engineering charges, to be agreed in advance by the parties. Successful enhancement projects may
result in a discount on Magnetrons.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Agreement may be terminated: 1) by either party following breach or default by the other
party and notice with 90&nbsp;days&#146; right to cure, in which case certain payments are due to the
aggrieved party, 2) by either party if the other party becomes insolvent, makes arrangements with
creditors, appoints a receiver or liquidates, 3) by the Company if issues arise from the Company&#146;s
audit of E2V that would cause the Company to fail to meet its regulatory and quality obligations
with respect to the System, or 4) by either party for any reason following 6&nbsp;months&#146; notice and a
last time buy option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The foregoing discussion of the terms and conditions of the Agreement does not purport to be
complete and is subject to and qualified in its entirety by, the Agreement as redacted in
accordance with a request for confidential treatment, which is attached as Exhibit&nbsp;10.1 hereto and
incorporated herein by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">(d)&nbsp;Exhibits.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">10.1 *
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Magnetron Subscription Agreement with e2v Inc. and e2v Technologies
(UK)&nbsp;Limited dated April&nbsp;24, 2009 and effective May&nbsp;1, 2009</DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Confidential treatment has been requested for portions of this exhibit. These portions have
been omitted from the Form 8-K and submitted separately to the Securities and Exchange Commission.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>TOMOTHERAPY INCORPORATED</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Dated: April 29, 2009&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">
<I>/s/ Stephen C. Hathaway</I>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Stephen C. Hathaway&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer and Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">10.1 *
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Magnetron Subscription Agreement with e2v Inc. and e2v Technologies
(UK)&nbsp;Limited dated April&nbsp;24, 2009 and effective May&nbsp;1, 2009</DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Confidential treatment has been requested for portions of this exhibit. These portions have been
omitted from the Form 8-K and submitted separately to the Securities and Exchange Commission.</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c84446e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 18556}]
{"company-data": {"conformed-name": "TomoTherapy Inc", "cik": "0001317872", "assigned-sic": "3845", "irs-number": "000000000"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33452", "film-number": "09779305"}, "business-address": {"street1": "1240 DEMING WAY", "city": "MADISON", "state": "WI", "zip": "53717-1954"}, "mail-address": {"street1": "1240 DEMING WAY", "city": "MADISON", "state": "WI", "zip": "53717-1954"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2009
TOMOTHERAPY INCORPORATED
(Exact name of registrant as specified in its charter)
Wisconsin
001-33452
39-1914727
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1240 Deming Way
Madison, Wisconsin
53717
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(608) 824-2800
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On April 24, 2009, TomoTherapy Incorporated (the "Company") entered into a Magnetron
Subscription Agreement (the "Agreement") with an effective date of May 1, 2009, with e2v Inc.,
having a business address at 520 White Plains Road, Suite 450, Tarrytown, New York, 10591, and e2v
Technologies (UK) Limited having its principal place of business at 106 Waterhouse Lane,
Chelmsford, CM1 2QU, United Kingdom (collectively, "E2V"), for the manufacture, purchase, and sale
of magnetrons (the "Magnetrons"). The Agreement is in addition to the Long-Term Purchase Agreement
dated December 22, 2008, between the Company and E2V for the purchase and sale of solid state
modulators, modulator accessories and magnetron accessories. The parties were previously doing
business for the purchase and sale of the Magnetrons strictly through purchase orders.
A magnetron is a key component in radiation therapy systems, used to supply radio frequency
energy to the linear accelerator.
Pursuant to the Agreement, the Company committed to purchasing all of its manufacturing
requirements for Magnetrons from E2V for the duration of the Agreement, commencing with an initial
36-month term. The Company has no minimum purchase obligation.
Pursuant to the Agreement, the parties designed a Magnetron Subscription Program ("MSP"),
whereby the Company will pay E2V an agreed subscription price per TomoTherapy Hi Art system (the
"System") listed in the subscription pool, payable monthly, to cover purchase, repair and
replacement for Magnetrons used in such Systems. Rather than providing a warranty, E2V provides a
repair and replacement program for the Magnetron on each System in the subscription pool. A credit
will be applied towards the first year's MSP price for Magnetrons already in use by the Company,
based on the average remaining life of the Magnetrons.
E2V may adjust the subscription price accordingly if there is a 10% or greater change in the
number of beam on hours per System, taking into account evidence from the Company regarding whether
the change in beam on hours has affected the Magnetron consumption rate. The subscription price
may also be adjusted down following successful improvement initiatives by the Company.
Payment is due 45 days from the invoice date and E2V allows a total credit line of $2.5
million for all products and services supplied to the Company, to be evaluated by the parties as
necessary.
The parties agreed to convert the agreed upon subscription price from British pounds to U.S.
dollars on the next business day after May 1, 2009 and each year of the Agreement thereafter, based
on a 12 month forward rate exchange rate lock.
The Company may purchase some Magnetrons outside of the MSP in order to build up or adjust
service inventory or for new product development work. Magnetrons purchased outside the MSP will
be covered under E2V's standard warranty against defects in materials and workmanship and failure
to meet the Company's specifications.
The Company may reject Magnetrons that do not conform to the Company's specifications by
giving written notice to E2V within 45 days from delivery. E2V may charge the Company a monthly
fee calculated based upon an estimated number of returned Magnetrons that the parties estimate that
E2V will determine do meet the agreed specifications even though the Company has rejected them ("No
Fault Found Fee"). Such No Fault Found Fee is subject to periodic adjustment if the actual number
of returned Magnetrons differs substantially from the estimated number. In the Agreement, the
parties affirmed their intention to collaborate to better align the Magnetron specifications with
the Company's performance expectations and testing procedures to attempt to reduce or eliminate the
No Fault Found Fee.
In the event that any Magnetron is replaced by E2V with a new product or major revision, E2V
has agreed to give the Company 180 days' written notice before implementation. The Company may
reject
such new or revised product and may require E2V to supply the Company with unchanged
Magnetrons in accordance with the blanket purchase order quantities.
In the Agreement, the parties affirmed their intention to collaborate to improve the life
performance of the Magnetrons. To that end, E2V agreed to include enhancement programs within the
MSP, it being understood that certain other investigative work would incur non-recurring
engineering charges, to be agreed in advance by the parties. Successful enhancement projects may
result in a discount on Magnetrons.
The Agreement may be terminated: 1) by either party following breach or default by the other
party and notice with 90 days' right to cure, in which case certain payments are due to the
aggrieved party, 2) by either party if the other party becomes insolvent, makes arrangements with
creditors, appoints a receiver or liquidates, 3) by the Company if issues arise from the Company's
audit of E2V that would cause the Company to fail to meet its regulatory and quality obligations
with respect to the System, or 4) by either party for any reason following 6 months' notice and a
last time buy option.
The foregoing discussion of the terms and conditions of the Agreement does not purport to be
complete and is subject to and qualified in its entirety by, the Agreement as redacted in
accordance with a request for confidential treatment, which is attached as Exhibit 10.1 hereto and
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Number
Description
10.1 *
Magnetron Subscription Agreement with e2v Inc. and e2v Technologies
(UK) Limited dated April 24, 2009 and effective May 1, 2009
*
Confidential treatment has been requested for portions of this exhibit. These portions have
been omitted from the Form 8-K and submitted separately to the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TOMOTHERAPY INCORPORATED
Dated: April 29, 2009
By:
/s/ Stephen C. Hathaway
Stephen C. Hathaway
Chief Financial Officer and Treasurer
EXHIBIT INDEX
Number
Description
10.1 *
Magnetron Subscription Agreement with e2v Inc. and e2v Technologies
(UK) Limited dated April 24, 2009 and effective May 1, 2009
*
Confidential treatment has been requested for portions of this exhibit. These portions have been
omitted from the Form 8-K and submitted separately to the Securities and Exchange Commission.